Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study

Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study

ABSTRACT Background Envafolimab is a novel immune checkpoint inhibitor (ICI) with several advantages due to its subcutaneous administration. Phases I and II randomized controlled trials have demonstrated promising efficacy in treating colorectal and gastric cancer. However, the safety and efficacy o...

Full description

Saved in:
Bibliographic Details
Main Authors: Zixuan Dou, Li Wang, Meng Rui, Yulong Yang, Yunzhi Zhou, JieLi Zhang, Qiuhong Zhao, Mengzhao Wang, Hanping Wang, Xiaotong Zhang, Xiaoxia Cui, Xiaoyan Si, Li Zhang
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Thoracic Cancer
Subjects:
advanced lung cancer
Envafolimab
immune checkpoint inhibitor
immunotherapy
subcutaneous injection
Online Access:https://doi.org/10.1111/1759-7714.70101
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.70101

Similar Items